October 14, 2015 – OICR, UHN, Novera Therapeutics collaborate with Johnson & Johnson Innovation to accelerate the development drug candidates for haematological cancers.
July 10, 2015 – Turnstone Biologics Inc., a FACIT portfolio company, has announced the ongoing enrollment of the Marabex™ clinical trial assessing the safety and immune responses in patients with advanced or metastatic, MAGE-A3-expressing solid tumours.
Read More from Turnstone Biologics Announces Enrollment in Landmark Oncolytic Vaccine Trial
May 26, 2015 – Mr. Beshar’s appointment strengthens Fluorinov’s leadership team, adding financial and pharmaceutical industry expertise as Fluorinov accelerates its clinical development activities.
Read More from Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors
May 4, 2015 – FACIT and its partners are pleased to announce the formation of Turnstone Biologics Inc., a biotechnology company focussed on developing treatments for cancer that harness the patient’s own immune system.
May 4, 2015 – With extensive experience guiding biotech companies in matters including corporate development and clinical strategy, Dr. Garceau’s appointment strengthens Fluorinov’s leadership team and adds significant regulatory expertise as Fluorinov transitions to clinical development.
January 7, 2015 – TORONTO, ON (January 07, 2015) – FACIT and Fluorinov Pharma announced today an investment in the development of highly potent inhibitors of key bromodomain targets.
July 14, 2014 – BDC Capital joined as a new investor and Dion Madsen, Senior Managing Partner at BDC Capital, will join Xagenic’s Board of Directors.
Read More from Xagenic Announces Second Closing of $25.5M Series B Financing
May 28, 2014 – XLV, a MaRS Innovation start-up company based in Thunder Bay, closed a $3 million Series A investment round with Boston-based Bernard M. Gordon Charitable Remainder Unitrust.
Read More from XLV Diagnostics Inc. secures a $3 Million Series A investment
April 24, 2014 – The candidate drugs have shown excellent preliminary safety profiles, improved treatment and expect to have fewer sedative side effects.
Read More from Fluorinov, FACIT and OICR announce novel candidate drugs
February 13, 2014 – With the closing of the acquisition, Fluidigm adds a high-parameter single-cell protein analysis platform to its industry-leading single-cell genomics platforms.
Read More from Fluidigm Completes Acquisition of DVS Sciences